VEGFA and Abnormal retinal morphology: Although anti-VEGF agents are the first-line treatment for various angiogenesis-related retinal diseases, it is not clear how the anti-VEGF antibody can accelerate the risks of systemic complications after intravitreal injection in premature infants (176).